Key Points
- CEO Helen Torley sold 20,000 shares on April 2 under a Rule 10b5‑1 plan at an average price of $64.24, generating $1,284,800 and reducing her stake by 2.54% to 767,780 shares (worth about $49.3M).
- Torley has sold a total of 80,000 shares in recent months (Feb–Apr), raising roughly $5.69M from those transactions, indicating a pattern of pre‑arranged insider sales.
- Halozyme reported an EPS miss (‑$0.24 vs. $1.92 expected) though revenue of $451.8M beat estimates and was up 51.6% year‑over‑year; analysts hold a consensus rating of “Hold” with an average target of $78.56.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $49,322,187.20. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
- On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $1,393,800.00.
- On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $78.64, for a total value of $786,400.00.
- On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00.
Halozyme Therapeutics Trading Down 1.4%
Shares of Halozyme Therapeutics stock opened at $64.49 on Friday. The company has a market capitalization of $7.64 billion, a P/E ratio of 25.90, a price-to-earnings-growth ratio of 0.26 and a beta of 1.03. The stock has a fifty day simple moving average of $70.03 and a 200 day simple moving average of $69.46. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics's revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the business posted $1.26 earnings per share. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, February 19th. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, February 21st. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a report on Thursday, February 19th. Finally, The Goldman Sachs Group reaffirmed a "sell" rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $78.56.
Check Out Our Latest Stock Report on Halozyme Therapeutics
Institutional Trading of Halozyme Therapeutics
A number of large investors have recently added to or reduced their stakes in the stock. Root Financial Partners LLC bought a new stake in Halozyme Therapeutics in the third quarter worth about $25,000. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 343 shares during the period. Measured Wealth Private Client Group LLC increased its stake in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Richardson Financial Services Inc. increased its stake in shares of Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 198 shares during the last quarter. Finally, Clearstead Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 265 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
